Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease

NCT00207766 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00207766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00207766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACCENT II - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease
Lead sponsor
Centocor, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2000
Completion date
August 31, 2006
Enrollment
306 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease